Lotus Pharmaceutical Co (美時化學製藥) has received approval from Japan’s Pharmaceuticals and Medical Devices Agency for its generic version of blood cancer drug Revlimid (lenalidomide), boosting its shares by as much as 3.54 percent in early Taipei trading yesterday.
The approval was for 2.5mg and 5mg capsules of lenalidomide, which it jointly developed with Japan’s Fuji Pharma Corp, Lotus Pharmaceutical said in a regulatory filing on Tuesday.
Lotus Pharmaceutical was responsible for developing the lenalidomide formula — the company’s first high-value generic product in Japan, while Fuji Pharma ran local bioequivalence studies of the drug.
Photo: Reuters
With the approval, Lotus Pharmaceutical is to supply the finished product to Fuji Pharma for commercialization in Japan. The companies expect to launch the product in Japan this year.
Sales of Revlimid in Japan totaled about US$282 million last year, Lotus Pharmaceutical said, citing data from life sciences researcher Iqvia Institute.
As of the second quarter, only Osaka, Japan-based Sawai Pharmaceutical Co had obtained agency approval for lenalidomide, but its generic product has not yet been marketed in the Japanese market, Lotus Pharmaceutical said.
“Lotus and Fuji are among the first to market their product in Japan and gain a good market share there,” Capital Investment Management Corp (群益投顧) said in a note yesterday. “Lotus received 16 approvals for its generic products worldwide in the second quarter, which is a remarkable achievement and will gradually contribute to its revenue and royalty income in the future.”
Lotus Pharmaceutical shares surged in early morning trading yesterday before retreating to close up 1.71 percent at NT$268.
Capital Investment gave Lotus Pharmaceutical a “buy” rating with a 12-month target price of NT$295.
Lotus Pharma’s net profit more than tripled to NT$1.27 billion (US$39.82 million) in the second quarter, up 286 percent from NT$327.67 million in the same period last year, the company said on Tuesday.
That translated into earnings per share (EPS) of NT$4.85, the best second-quarter performance in its history.
In the first half of the year, EPS totaled NT$9.43, up 217 percent year-on-year, it said.
Lotus Pharma’s cumulative revenue in the first seven months totaled NT$11.25 billion, up 58.16 percent from the same period last year, company data showed.
With better business prospects, the company projected annual revenue growth of 13 to 15 percent for this year, higher than its previous estimate of 7 to 10 percent, while gross margin is expected to reach 55 percent, compared with 50 percent in its earlier forecast.
A proposed 100 percent tariff on chip imports announced by US President Donald Trump could shift more of Taiwan’s semiconductor production overseas, a Taiwan Institute of Economic Research (TIER) researcher said yesterday. Trump’s tariff policy will accelerate the global semiconductor industry’s pace to establish roots in the US, leading to higher supply chain costs and ultimately raising prices of consumer electronics and creating uncertainty for future market demand, Arisa Liu (劉佩真) at the institute’s Taiwan Industry Economics Database said in a telephone interview. Trump’s move signals his intention to "restore the glory of the US semiconductor industry," Liu noted, saying that
On Ireland’s blustery western seaboard, researchers are gleefully flying giant kites — not for fun, but in the hope of generating renewable electricity and sparking a “revolution” in wind energy. “We use a kite to capture the wind and a generator at the bottom of it that captures the power,” said Padraic Doherty of Kitepower, the Dutch firm behind the venture. At its test site in operation since September 2023 near the small town of Bangor Erris, the team transports the vast 60-square-meter kite from a hangar across the lunar-like bogland to a generator. The kite is then attached by a
Foxconn Technology Co (鴻準精密), a metal casing supplier owned by Hon Hai Precision Industry Co (鴻海精密), yesterday announced plans to invest US$1 billion in the US over the next decade as part of its business transformation strategy. The Apple Inc supplier said in a statement that its board approved the investment on Thursday, as part of a transformation strategy focused on precision mold development, smart manufacturing, robotics and advanced automation. The strategy would have a strong emphasis on artificial intelligence (AI), the company added. The company said it aims to build a flexible, intelligent production ecosystem to boost competitiveness and sustainability. Foxconn
Leading Taiwanese bicycle brands Giant Manufacturing Co (巨大機械) and Merida Industry Co (美利達工業) on Sunday said that they have adopted measures to mitigate the impact of the tariff policies of US President Donald Trump’s administration. The US announced at the beginning of this month that it would impose a 20 percent tariff on imported goods made in Taiwan, effective on Thursday last week. The tariff would be added to other pre-existing most-favored-nation duties and industry-specific trade remedy levy, which would bring the overall tariff on Taiwan-made bicycles to between 25.5 percent and 31 percent. However, Giant did not seem too perturbed by the
RSS